Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565763 | 0.83 | KDM1A (0.39) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL14587286 | 0.82 | KDM1A (0.46) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL14587287 | 0.82 | KDM1A (0.46) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL16353667 | 0.82 | NOTUM (0.47) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL6648174 | 0.82 | NOTUM (0.47) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL16385108 | 0.82 | NOTUM (0.47) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL16353535 | 0.82 | NOTUM (0.47) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL8567392 | 0.81 | KDM1A (0.38) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL30632531 | 0.81 | KDM1A (0.51) | KDM1ABCHENAMPTHDAC1HDAC6 | |
| SCHEMBL26115263 | 0.81 | KDM1A (0.51) | KDM1ABCHENAMPTHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | KDM1A 1397/4885BCHE 910/4885NAMPT 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.